Oliver Lagore Vanvalin Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12	Closed	-$5.02K	–	822
2024 Q1	$5.02K	Hold	12	–	–	﹤0.01%	509
2023 Q4	$4.88K	Hold	12	–	–	﹤0.01%	528
2023 Q3	$4.17K	Hold	12	–	–	﹤0.01%	586
2023 Q2	$4.22K	Hold	12	–	–	﹤0.01%	590
2023 Q1	$3.78K	Hold	12	–	–	﹤0.01%	523
2022 Q4	$3.46K	Hold	12	–	–	﹤0.01%	509
2022 Q3	$3K	Hold	12	–	–	﹤0.01%	509
2022 Q2	$3K	Hold	12	–	–	﹤0.01%	480
2022 Q1	$3K	Buy	+12	New	+$2.85K	﹤0.01%	485

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's VRTX Position: Q2 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 12 shares — an estimated $5.02K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in VRTX in Q1 2022 and held it in 9 quarters. The position peaked at $5.02K in Q1 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Oliver Lagore Vanvalin Investment Group reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 12 Vertex Pharmaceuticals shares in Q2 2024, an estimated $5.02K.
Oliver Lagore Vanvalin Investment Group first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 9 quarters.
Oliver Lagore Vanvalin Investment Group's Vertex Pharmaceuticals position peaked at $5.02K in Q1 2024.
1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2024, filed 15 Aug 2024.